Tatiana I. Rogounovitch

Dr. Tatiana I. Rogounovitch

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2021 in Thyroid®
Verified
Journal Article
Closed access
TBTetiana Bogdanova
Tetiana Bogdanova
VSVladimir Saenko
Vladimir Saenko
YHYuko Hashimoto
Yuko Hashimoto
MHMitsuyoshi Hirokawa
Mitsuyoshi Hirokawa
LZLiudmyla Yu. Zurnadzhy
Liudmyla Yu. Zurnadzhy
SSShinichi Suzuki
Shinichi Suzuki
Background: A significant increase in the incidence of papillary thyroid carcinoma (PTC) in subjects exposed to radiation at a young age is a well-documented health consequence of the Chernobyl accident. The ongoing Thyroid Ultrasound Examination (TUE) program in children and adolescents of Fukushima Prefecture in Japan also indicated a high prevalence of PTC although its attribution to radiation exposure is a subject of debate. The objective of this study was to perform histopathological analysis of tumor architecture and invasive properties in (i) radiogenic post-Chernobyl and sporadic PTCs from Ukraine, and (ii) PTCs in patients from Fukushima and other Prefectures of Japan of comparable age groups. Methods: The Ukrainian radiogenic PTCs included 245 PTCs from patients who resided in three highly 131 I-contaminated regions and 165 sporadic PTCs diagnosed in residents of the same regions who were born after the accident and therefore not exposed to radioiodine. The Japanese series included 115 PTCs detected during the preliminary and the first full-scale surveys of the TUE in Fukushima and 223 PTCs from patients resident in other Prefectures. All of the subjects were included in the main statistical analysis. Three additional analyses were performed limiting the subjects to children, adolescents, and adults. Results: Ukrainian radiogenic PTC was characterized by the higher frequency of tumors with a dominant solid-trabecular growth pattern and higher invasiveness, more frequent extrathyroidal extension, lymphatic/vascular invasion, regional and distant metastases when compared with sporadic Ukrainian PTC. The integrative “invasiveness score,” based on five cancer characteristics, was also higher in the radiogenic group. The differences were most pronounced in children. In contrast, no significant differences in tumor morphology or invasiveness were observed between the two Japanese groups or the three age subgroups. The only statistically significant findings were the higher proportion of male patients, smaller mean tumor size, and higher frequency of T1b tumors in the Fukushima group. Conclusions: The difference in morphological features that indicate biological behavior of PTC between the radiation-related and sporadic groups from Ukraine, together with the lack of such in the two groups from Japan, strongly suggest a nonradiogenic etiology of PTC from Fukushima and other Prefectures.

1 January 2006 in Radiation Research
Verified
Journal Article
Closed access
PDF file
APA. Podtcheko
A. Podtcheko
AOA. Ohtsuru
A. Ohtsuru
HNH. Namba
H. Namba
VSVladimir Saenko
Vladimir Saenko
DSD. Starenki
D. Starenki
SYS. Yamashita
S. Yamashita
Podtcheko, A., Ohtsuru, A., Namba, H., Saenko, V., Starenki, D., Palona, I., Sedliarou, I., Rogounovitch, T. and Yamashita, S. Inhibition of ABL Tyrosine Kinase Potentiates Radiation-Induced Terminal Growth Arrest in Anaplastic Thyroid Cancer Cells. Radiat. Res. 165, 35–42 (2006). Gleevec®, a selective tyrosine kinase inhibitor, retarded the growth of anaplastic thyroid cancer cell lines in vitro and in vivo through selective inhibition of ABL tyrosine kinase activity. In the present study, we investigated the ability of Gleevec® to modulate the in vitro and in vivo radiation response of anaplastic thyroid cancer cells. Cell growth assays, colony formation assays and xenograft models were used to quantify the radiosensitizing effect of Gleevec® in cells of the anaplastic thyroid cancer cell lines ARO and FRO. FACS, Western blotting and histochemical techniques were employed to study the mechanisms of radiation response after exposure to Gleevec®. Gleevec® (7.0 μM) increased the anti-proliferative effect of radiation on the growth ARO and FRO cells in vitro. Clonogenic analysis demonstrated that Gleevec® reduced cell survival after irradiation. Gleevec® combined with radiation produced an increase in tumor growth inhibition compared to treatment with either modality alone in mice bearing anaplastic thyroid cancer xenografts. The drug suppressed radiation-induced ABL activation and promoted CDKN1A (p21cip1) accumulation in irradiated anaplastic thyroid cancer cells. Gleevec® had an additional effect on radiation-induced apoptosis in cells of both cell lines and potentiated the induction of terminal growth arrest accompanied by the expression of senescence-associated β-galactosidase. The antitumor effect of Gleevec® is potentiated in adjunctive therapy with radiation not only due to inhibition of proliferative cell growth with transient cell cycle arrest and apoptosis, but also due to the terminal growth arrest associated with senescence, suggesting that tumor cell senescence is a mechanism for tumor targeting therapy in combination with ionizing radiation.

30 November 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LZLiudmyla Zurnadzhy
Liudmyla Zurnadzhy
TBTetiana Bogdanova
Tetiana Bogdanova
TRTatiana I. Rogounovitch
Tatiana I. Rogounovitch
MIMasahiro Ito
Masahiro Ito
MOMaryan Ostafiychuk
Maryan Ostafiychuk
VSVladimir Saenko
Vladimir Saenko
Histopathological changes in the fusion oncogene-driven papillary thyroid carcinomas (PTCs) from children and adolescents exposed to Chernobyl fallout have been extensively studied. However, characteristics of the radiogenic BRAFV600E-positive PTCs, whose proportion is growing with time, are not well described yet. We analyzed the relationship between the BRAFV600E status (determined immunohistochemically with the VE1 antibody) and the clinicopathological features of 247 radiogenic and 138 sporadic PTCs from young Ukrainian patients aged ≤28 years. The frequency of BRAFV600E was increasing with patient age, consistently remaining lower in radiogenic PTCs. In both etiopathogenic groups, the BRAFV600E-positive PTCs more frequently had a dominant papillary growth pattern, smaller tumor size, higher Ki67 labeling index, and a frequency of the major indicators of tumor invasiveness that is lower than or equal to that of the BRAFV600E-negative tumors. Comparison of the BRAFV600E-positive PTCs across the groups found a virtual absence of differences. In contrast, the BRAFV600E-negative radiogenic PTCs displayed less frequent dominant papillary and more frequent solid growth patterns, lower Ki67 labeling index, and higher invasiveness than the BRAFV600E-negative sporadic tumors. Thus, BRAFV600E is not associated with a more aggressive course of PTC in young patients regardless of etiology. The major clinicopathological differences between the radiogenic and sporadic PTCs are observed among the BRAFV600E-negative tumors.

15 March 2019 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
KOKenji Ohba
Kenji Ohba
NMNorisato Mitsutake
Norisato Mitsutake
MMMichiko Matsuse
Michiko Matsuse
TRTatiana I. Rogounovitch
Tatiana I. Rogounovitch
NNNobuhiko Nishino
Nobuhiko Nishino
Kenichi KakudoKenichi Kakudo
Kenichi Kakudo
Although papillary thyroid carcinoma (PTC)-type nuclear changes are the most reliable morphological feature in the diagnosis of PTC, the nuclear assessment used to identify these changes is highly subjective. Here, we report a noninvasive encapsulated thyroid tumor with a papillary growth pattern measuring 23 mm at its largest diameter with a nuclear score of 2 in a 26-year-old man. After undergoing left lobectomy, the patient was diagnosed with an encapsulated PTC. However, a second opinion consultation suggested an alternative diagnosis of follicular adenoma with papillary hyperplasia. When providing a third opinion, we identified a low MIB-1 labeling index and a heterozygous point mutation in the KRAS gene but not the BRAF gene. We speculated that this case is an example of a novel borderline tumor with a papillary structure. Introduction of the new terminology "noninvasive encapsulated papillary RAS-like thyroid tumor (NEPRAS)" without the word "cancer" might relieve the psychological burden of patients in a way similar to the phrase "noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)."

5 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TRTatiana I. Rogounovitch
Tatiana I. Rogounovitch
SMSvetlana V. Mankovskaya
Svetlana V. Mankovskaya
MFMikhail V. Fridman
Mikhail V. Fridman
TLTatiana A. Leonova
Tatiana A. Leonova
VKVictor A. Kondratovitch
Victor A. Kondratovitch
VSVladimir Saenko
Vladimir Saenko
Childhood papillary thyroid carcinoma (PTC) diagnosed after the Chernobyl accident in Belarus displayed a high frequency of gene rearrangements and low frequency of point mutations. Since 2001, only sporadic thyroid cancer occurs in children aged up to 14 years but its molecular characteristics have not been reported. Here, we determine the major oncogenic events in PTC from non-exposed Belarusian children and assess their clinicopathological correlations. Among the 34 tumors, 23 (67.6%) harbored one of the mutually exclusive oncogenes: 5 (14.7%) BRAFV600E, 4 (11.8%) RET/PTC1, 6 (17.6%) RET/PTC3, 2 (5.9%) rare fusion genes, and 6 (17.6%) ETV6ex4/NTRK3. No mutations in codons 12, 13, and 61 of K-, N- and H-RAS, BRAFK601E, or ETV6ex5/NTRK3 or AKAP9/BRAF were detected. Fusion genes were significantly more frequent than BRAFV600E (p = 0.002). Clinicopathologically, RET/PTC3 was associated with solid growth pattern and higher tumor aggressiveness, BRAFV600E and RET/PTC1 with classic papillary morphology and mild clinical phenotype, and ETV6ex4/NTRK3 with follicular-patterned PTC and reduced aggressiveness. The spectrum of driver mutations in sporadic childhood PTC in Belarus largely parallels that in Chernobyl PTC, yet the frequencies of some oncogenes may likely differ from those in the early-onset Chernobyl PTC; clinicopathological features correlate with the oncogene type.

30 January 2008
Verified
Journal Article
Closed access
ISIlya Sedliarou
Ilya Sedliarou
MMMichiko Matsuse
Michiko Matsuse
VSVladimir Saenko
Vladimir Saenko
TRTatiana I. Rogounovitch
Tatiana I. Rogounovitch
YNYuka Nakazawa
Yuka Nakazawa
SYShunichi Yamashita
Shunichi Yamashita